Canadian-Colombian medical cannabis extracts producer PharmaCielo Ltd PCLO PCLOF added another Brazilian-based customer to its roster.
The company announced this week that it signed a sales agreement and already completed an initial commercial sale of CBD Isolate to an undisclosed pharmaceutical company, one of the first to be fully licensed in Brazil by the Health Regulatory Agency (ANVISA) to produce cannabinoid-based products.
According to PharmaCielo, this pharma client with a presence in numerous Latin American, European and Asian countries intends to procure a range of cannabis extracts including CBD Isolate, Full Spectrum CBD, Full Spectrum THC and THC Distillate once final product registration and import permits are granted by the Brazilian authorities.
Henning von Koss, CEO of PharmaCielo noted in a statement to Benzinga that, “With this sales agreement and initial commercial shipment our go-to-market approach, to partner with more sophisticated finished-product manufacturers and early integration into their supply chain with higher-value formulations, starts to yield results.”
This is PharmaCielo’s first signed sales agreement and the third engagement with a large Brazilian customer after the company announced in late April it delivered shipments to two large Brazilian Phyto-Therapeutics and pharmaceutical companies.
Encuentra nuestro contenido en Español en El Planteo:
- Las Cuatro Grandes Compañías de Cannabis en Colombia
- PharmaCielo Realiza Envíos Precomerciales de Cannabis de Colombia a Brasil
Photo: Courtesy
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.